ISPOR Releases Top 10 HEOR Trends Report for 2022-2023

By Staff Writer

January 17, 2023

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a renowned professional society in Health Economics and Outcomes Research (HEOR). Biennially, it publishes a report, outlining the ISPOR Top 10 HEOR Trends. This article explores the 2022-2023 top trends, heavily influenced by the COVID-19 pandemic, and their implications for the healthcare industry.

Real-world Evidence (RWE) – The Number One Trend

RWE has been identified as the top trend for 2022-2023. Its significance has grown due to its crucial role in addressing the pandemic. Health data, which is integral to RWE, also joins the trends list at number nine.

Health Equity – A New Entrant in the Top Trends

The pandemic has starkly highlighted health disparities and their devastating impact. As a result, health equity has emerged as a top trend, ranking third on the list.

Public Health and Health Technology Assessment (HTA) – Rising Trends

Public health has also been elevated in the trends list, ranking seventh, no doubt due to the pandemic’s impact. HTA enters the list at number eight, underlining the importance of evaluating healthcare interventions.

Artificial Intelligence – A Key Player in the Top Trends

Artificial Intelligence (AI) has made its mark, joining the top trends at number ten. It’s clear that healthcare data and AI are becoming increasingly intertwined, driving innovation and efficiency in the sector.


These top trends in HEOR provide valuable insights for all healthcare stakeholders, from researchers and academicians to life sciences industry professionals and patients. They highlight the importance of informed health decisions backed by rigorous, proven methodologies.

 

Reference url

Recent Posts

TLX250-CDx imaging agent
      

Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis

🔍 Could a new imaging agent revolutionize kidney cancer diagnosis?

The FDA’s acceptance of the Biologics License Application for TLX250-CDx marks a significant milestone in the fight against clear cell renal cell carcinoma (ccRCC). This investigational PET imaging tool promises non-invasive, high-accuracy diagnostics, which could lead to improved patient outcomes and better-targeted treatment plans.

Curious about its potential impact on healthcare and market dynamics? Dive into the full article to learn more!

#SyenzaNews #medicalimaging #oncology #HealthcareInnovation

personalized cancer vaccine
         

Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients

🌟 Could personalized cancer vaccines be the future of cancer treatment?

A recent phase I clinical trial has shown promising results for a personalized cancer vaccine in patients with high-risk clear cell renal cell carcinoma (RCC). All participants developed immune responses, and notably, none experienced recurrence at a median follow-up of over 40 months! With a favorable safety profile, this approach may pave the way for more effective adjuvant therapies in oncology.

Jump into the full findings and see how this advancement could change the landscape of cancer treatment!

#SyenzaNews #oncology #biotechnology #innovation

ivonescimab clinical trials
    

Advancing Cancer Treatment: Ivonescimab’s Potential and Strategic Collaboration with Pfizer

🚀 Exciting news in the fight against cancer!

Summit Therapeutics has announced a groundbreaking collaboration with Pfizer to launch clinical trials for ivonescimab, an innovative PD-1/VEGF bispecific antibody. This partnership aims to evaluate the safety and effectiveness of ivonescimab in combination with Pfizer’s antibody drug conjugates across various solid tumors, including non-small cell lung cancer. 🌟

To learn more about this promising development and its potential impact on oncology treatment, dive into the full article!

#SyenzaNews #oncology #clinicaltrials #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.